Sharma 2002a.

Methods	Study design: open‐label, parallel RCT Duration of study: not reported Duration of follow‐up: 6 months
Participants	Country: India Setting: single centre Inclusion criteria: kidney transplant recipients Number: treatment group (30); control group (30) Mean age ± SD (years): treatment group (36.5 ± 9.3); control group (38 ± 13.8) Sex (M/F): treatment group (26/4); control group (26/4) Exclusion criteria: not reported
Interventions	Treatment group Alendronate (oral): 10 mg/d Control group No treatment Co‐interventions Calcium Vitamin D or analogue
Outcomes	BMD by DEXA at spine
Notes	Abstract‐only publications. No full‐text publication identified Funding source: not reported Trial registration: not applicable as study published before end of 2005
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Patient‐centred outcomes not reported systematically
Other bias	Unclear risk	Insufficient information to permit judgement